Nimotuzumab (powder)
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) [1][2].
Product Specifications
CAS Number
780758-10-3
UNSPSC
12352203
Target
EGFR
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[Nimotuzumab(powder)]
Molecular Weight
(147.58 kDa)
References & Citations
[1]Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382.|[2]Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1 (1) :41-8.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740445-100 1x 100 µL
Muscle Specific Actin (HHF35), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
PKSH033270-01 10 µg
Recombinant Human β-NGF/NGFB Protein (aa 122-239, Human Cells)
Sign In for Pricing
View Details